|Awarded On||February 21, 2019|
|Title||Preclinical Development of a Novel T-ALL Therapeutic Antibody|
|Program||Product Development Research|
|Award Mechanism||Seed Awards for Product Development Research|
|Institution/Organization||Allterum Therapeutics, LLC|
|Principal Investigator/Program Director||Atul Varadhachary|
|Cancer Sites||Leukemia, Lymphoma|
*Pending contract negotiation
Allterum Therapeutics, a Houston, TX based company, is developing a new drug for the treatment of pediatric T-cell acute lymphoblastic leukemia – a common form of childhood cancer. Although current treatments are effective for a majority of children with this disease, approximately 20% of patients experience a recurrence of the disease. Unfortunately, no drugs exist to effectively help patients who experience this relapse.
Our drug is an antibody which is able to much more specifically target and kill cancer cells without the broader side-effects typically observed with conventional chemotherapies. Therefore, Allterum Therapeutics is addressing a major unmet medical need, as our drug is expe...